



SOPHiA GENETICS announces CE-IVD marking of its genomic test for leukemia detection

The Myeloid Solution by SOPHiA GENETICS is the best-in-class molecular diagnostic application which empowers clinicians to more precisely diagnose hematological disorders

Lausanne, SWITZERLAND - 06th February 2018: SOPHiA GENETICS, global leader in Data-Driven Medicine, unveiled today the world's first capture-based myeloid clinical solution to receive the CE-IVD mark. The standardized molecular diagnostic application represents a breakthrough in diagnostics for hematological diseases. This includes diseases such as leukemia, which account for 2.5% of all cancers worldwide, and 30% of cancers in children and young adults¹. This test comprehensively covers genes associated with hematological disorders and provides clinicians with a complete solution which rapidly and precisely analyzes their patients' DNA.

The CE-IVD marked Myeloid Solution by SOPHiA GENETICS guarantees unmatched performance in the analytical detection of genomic mutations responsible for myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN) and leukemia. It does this by providing high on-target reads percentage and coverage uniformity, even in GC-rich regions. Common technical limitations related to the analysis of key biomarkers such as *CEBPA*, *FLT3* and *CALR* are now overcome with this standardized solution.

The newly approved CE-IVD Myeloid Solution by SOPHiA GENETICS represents a major advancement in the personalization of cancer care. It will facilitate access for patients around the world to a comprehensive diagnostic solution that will identify approved treatment options based on the molecular footprint of each individual's cancer. This will

¹ http://www.euro.who.int/__data/assets/pdf_file/0005/97016/4.1.-Incidence-of-childhood-leukaemia-EDITED_layouted.pdf

aid the pharmaceutical industry to optimize biomarker-driven drug development and drug access to the right patients.

Though death rates associated with hematological disorders have decreased significantly in recent years, the number of new cases is steadily increasing. SOPHiA GENETICS' CE-IVD certified Myeloid Solution alleviates the time and complexity burden of traditional diagnostic technologies with a standardized and easy to adopt solution which empowers clinicians to more precisely diagnose patients with hematological disorders.

###

SOPHiA GENETICS: Global leader in Data-Driven Medicine, SOPHiA GENETICS is a health tech company which has developed SOPHiA AI, the most advanced technology for clinical genomics, helping healthcare professionals better diagnose and treat patients. The global network of 400 institutions from 55 countries that use the SOPHiA DDM[®] analytical platform powered by SOPHiA forms the world's largest clinical genomics community. By enabling the rapid adoption of genomic testing worldwide, turning data into actionable clinical insights, and sharing knowledge through its community, SOPHiA GENETICS is democratizing Data-Driven Medicine to save lives equally. The company's achievements were recognized by MIT Technology Review who ranked it amongst the 50 Smartest Companies in 2017. More info: <http://www.sophiagenetics.com>

SOPHiA GENETICS is on Twitter, follow [@SOPHiAGENETICS](https://twitter.com/SOPHiAGENETICS) | For media and journalist inquiries, please contact the SOPHiA GENETICS media relations team by either email or telephone: rchandramouli@sophiagenetics.com or +41 79 378 1543.